PTH-132 High rates of clinical response are maintained after switching from originator to biosimilar infliximab
Sign Up to like & getrecommendations! Published in 2019 at "Gut"
DOI: 10.1136/gutjnl-2019-bsgabstracts.191
Abstract: Introduction Biosimilar infliximab (BI) has been widely adopted in to clinical practice since launch in 2015. Switching patients with Inflammatory Bowel Disease (IBD) from originator infliximab (OI) to BI was endorsed by the BSG and… read more here.
Keywords: switch; biosimilar infliximab; clinical response; pre switch ... See more keywords